News
Company News: Agena Bioscience and Intermountain Healthcare Announce Research Collaboration To Advance Precision Medicine
Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue biopsy. The molecular tests augment laboratory services available worldwide from Intermountain Precision Genomics to advance precision medicine in cancer.
Company News: Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I
– Phenex drug discovery has now resulted in two clinical stage programs this year through research collaborations
Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6M US$ payment by Janssen. The milestone payment relates to a R&D collaboration between Phenex and Janssen, with a total potential value of 135 M USD, initiated in late 2012, to jointly discover RORgt inhibitors for the treatment of chronic inflammatory and autoimmune diseases.
Company News: Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is going to attend several industry conferences in the third quarter of 2017. The respective presentations will be made available on the company’s website.
Company News: Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
– First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced Phase I trial results demonstrating its IVAC® MUTANOME, an individualized RNA vaccine based on patient-specific mutations, induces strong immunogenicity as well as promising anti-tumor activity in high-risk patients with late-stage melanoma.